adp-ribose Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Female only (1)
Any (1)

Phase 2 (2)

Interventional (2)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)
University of Pennsylvania (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadmetastasis

I am/have/hadblood transfusion

I am/have/hadhysterectomy

I am/have/hadprimary peritoneal carcinoma

I am/have/haddebulking surgery

I am/have/hadmaintenance treatment

I am/have/hadskin cancer

I am/have/hadplatelet count

I am/have/hadsterilisation

I am/have/hadestimated creatinine clearance

I am/have/hadliver metastasis

I am/have/hadoophorectomy

I am/have/hadtumor treating fields therapy

I am/have/hadtreatment and maintenance

I am/have/hadrecurrent glioblastoma

I am/have/hadserum pregnancy test

I am/have/hadperipheral blood smear

I am/have/hadrecurrent ovarian cancer

I am/have/hadrenal function

added new label for I am/have/had

more

I am looking for

I am looking formelanoma

I am looking forcarboplatin

I am looking forolaparib

I am looking forparp inhibitor

I am looking foradp-ribose

I am looking forniraparib

I am looking forfollicle stimulating hormone

I am looking forluteinizing hormone

I am looking forpaclitaxel

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
For Females
Recruiting

NUVOLA TRIAL Open-label Multicentre Study

OLAPARIB in BRCA mutation carriers Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that causes synthetic lethality in BRCA1/2-deficient tumour cells. In patients with platinum-sensitive relapsed serous ovarian cancer, olaparib maintenance treatment significantly improved the duration of progression-free survival compared with placebo (hazard ratio [HR] 0.35 [95% CI …

measurable disease

melanoma

olaparib

metastasis

blood transfusion

0 views
19 Feb, 2024

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Neurology
Recruiting

Niraparib/TTFields in GBM

Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).

renal function test

karnofsky performance status

recurrent glioblastoma

MRI

glioblastoma

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.